Every Form 4 that Outset Medical, Inc. (OM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow OM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OM filings page.
Outset Medical, Inc. (OM) reported that Chair and CEO Leslie Trigg sold 3,437 shares of Common Stock on August 17, 2026 at $4.39 per share. According to the disclosure, this was a mandatory “sell to cover” transaction to satisfy tax withholding obligations on the vesting of 9,319 RSU-based shares, and is described as not a discretionary trade. Following the sale, Trigg held 194,597 shares directly, plus indirect holdings of 41,666 shares through the Trigg 2002 Rev Trust and 584 shares through the Trigg Family Trust.
Outset Medical, Inc. (OM) reported that General Counsel John L. Brottem sold 2,632 shares of common stock on 2026-08-17 at $4.39 per share. According to the company’s disclosure, the shares were sold in a non-discretionary “sell to cover” transaction to satisfy tax withholding obligations arising from the vesting of 5,033 RSU-based shares granted in 2024 and 2025. After this transaction, Brottem directly holds 87,475 shares of Outset Medical common stock.
Outset Medical, Inc. (OM) reported that its Chief Financial Officer, Renee Gaeta, sold 4,543 shares of common stock on August 17, 2026 at $4.39 per share. After this transaction, Gaeta directly holds 180,840 shares. According to the company’s disclosure, the shares were sold in a “sell to cover” transaction to satisfy tax withholding obligations arising from the vesting of 12,322 RSU-based shares granted on June 10, 2025 and do not represent a discretionary trade.
Brottem John L. reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. reported that its General Counsel, John L. Brottem, received a grant of 59,830 restricted stock units (RSUs) of common stock on June 26, 2026. Each RSU represents one share of common stock. Following this award, his direct holdings total 90,107 shares. The RSUs vest 33.33% on June 26, 2027, with the remaining 66.67% vesting in equal quarterly installments over the next two years, subject to his continuous service.
Gaeta Renee reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc.’s Chief Financial Officer, Renee Gaeta, reported a grant of 71,630 shares of common stock in the form of restricted stock units. The award was granted at no cash cost and raises her direct holdings to 185,383 shares after the transaction.
Each RSU represents the right to receive one share of common stock if it vests. The units vest 33.33% on June 26, 2027, with the remaining 66.67% vesting in equal quarterly installments over the following two years, as long as she remains in continuous service.
Trigg Leslie reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. Chair and CEO Leslie Trigg received a grant of 99,160 restricted stock units (RSUs) of common stock as equity compensation. Each RSU represents the right to receive one share of common stock if vesting conditions are met.
The RSUs vest 33.33% on June 26, 2027, with the remaining 66.67% vesting in equal quarterly installments over the following two years on February 15, May 15, August 15, and November 15, subject to continued service. After this grant, Trigg holds 198,034 shares directly, plus indirect holdings of 584 shares via the Trigg Family Trust and 41,666 shares via the Trigg 2002 Rev Trust.
HACKETT PATRICK T reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. director Patrick T. Hackett received a grant of 10,667 shares of common stock as a stock award at a stated price of $0.00 per share. These RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders.
Following this grant, Hackett holds 105,839 shares of Outset Medical common stock directly. He also has indirect ownership of 41,666 shares through the Hackett Family Fund and 83,333 shares through the GST Trust as of the transaction date.
OBOYLE KEVIN C reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. director Kevin C. O’Boyle received an equity award in the form of restricted stock units covering 10,667 shares of common stock. The award was recorded at a price of $0.00 per share as a compensation grant, not a market purchase.
Following this award, O’Boyle directly holds 34,785 shares of Outset Medical common stock. According to the disclosure, 100% of the shares underlying these RSUs will vest upon the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders.
Prange Karen reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical director Karen Prange received a new equity award in the form of restricted stock units (RSUs). The grant covers 10,667 shares of common stock at no cash cost, increasing her direct holdings to 29,334 shares after the transaction.
According to the terms, 100% of the shares underlying these RSUs will vest on the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders. This award is compensation-related, not an open-market stock purchase.
LANG BRENT D. reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. director Brent D. Lang received a grant of 10,667 shares of Common Stock as a stock award at a stated price of $0.0000 per share. These shares represent the underlying restricted stock units.
According to the terms, 100% of the shares underlying these RSUs will vest upon the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders. Following this award, Lang holds 28,518 shares directly and 16,666 shares indirectly through the Lang Family Trust.
GROSSMAN D KEITH reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. director D. Keith Grossman reported an equity award and updated holdings. He received a grant of 10,667 shares of Common Stock at $0.00 per share, described in the footnote as shares underlying RSUs that will vest 100% on the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders. Following the grant, he holds 24,585 shares directly and 12,845 shares indirectly through the Grossman Fam Trust.
Drexler Karen reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. director Karen Drexler reported an equity award of common stock as compensation. She received 10,667 shares at a price of $0.00 per share, reflecting a grant rather than an open-market purchase or sale.
According to the filing, 100% of the shares underlying these RSUs will vest upon the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders. Following the grant, Drexler directly holds 21,317 shares of common stock and indirectly holds 2,083 shares through the Drexler Family Trust.
Outset Medical, Inc. Chief Financial Officer Renee Gaeta reported an open‑market sale of 17,672 shares of Common Stock at $4.94 per share. According to the disclosure, this was a required “sell to cover” transaction to satisfy tax withholding obligations tied to the vesting of 32,856 RSU-based shares.
The filing notes that the sale does not represent a discretionary trade by the executive. After the transaction, Gaeta directly holds 113,753 shares of Outset Medical Common Stock, indicating she retains a substantial equity stake following the tax‑related sale.
Outset Medical, Inc. director and Chair and CEO Leslie Trigg reported an open-market sale of 3,445 shares of Common Stock at $3.70 per share. According to the footnotes, this was a required sale to cover tax withholding obligations tied to the vesting of 9,319 RSU-based shares and did not represent a discretionary trade.
After the sale, Trigg held 98,874 Common Stock shares directly, along with 584 shares held indirectly through the Trigg Family Trust and 41,666 shares held indirectly through the Trigg 2002 Rev Trust, all as of May 15, 2026.
Outset Medical, Inc. executive vice president Marc Nash reported an open-market sale of 1,582 shares of common stock at $3.70 per share. According to the footnote, this was a required “sell to cover” transaction to pay tax withholding on the vesting of 4,277 RSU shares and was not a discretionary trade. After the sale, Nash directly holds 38,393 shares of Outset Medical common stock.
Outset Medical, Inc. General Counsel John L. Brottem reported an open-market sale of 2,638 shares of Common Stock at $3.70 per share. According to the footnotes, this was a required "sell to cover" transaction to satisfy tax withholding obligations tied to the vesting of 5,033 RSU-based shares and is not a discretionary trade. After this tax-related sale, Brottem directly holds 30,277 shares of Common Stock. A separate footnote notes a correction to a previously reported 2,842-share tax-related sale, revising it to 2,862 shares due to an administrative error.
Outset Medical, Inc. disclosed that investment entity BML Investment Partners, L.P., associated with major holder Leonard Braden Michael, acquired 323,000 shares of common stock at $5.00 per share. The shares were assigned upon expiration of short June 2026 put options held by the reporting owner.
Following this option assignment, BML Investment Partners, L.P. indirectly holds 2,519,701 shares of Outset Medical common stock. Mr. Leonard, as managing member of BML Capital Management, LLC, exercises voting and investment control over the fund’s holdings but disclaims beneficial ownership except to the extent of his pecuniary interest.
Outset Medical, Inc. insider activity shows entities associated with Michael Leonard exercising in-the-money derivatives to acquire additional common stock. BML Investment Partners, L.P. acquired 197,600 and 96,900 shares of common stock at $5.00 per share, bringing its indirectly held position to 2,196,701 shares. These holdings are managed by BML Capital Management, LLC, where Leonard is the managing member with investment and voting control, while he disclaims beneficial ownership beyond his pecuniary interest. The filing also notes outstanding indirect positions in short put options over additional common shares.
Elliott Derick A. reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. executive Elliott Derick A., EVP, Commercial, received a grant of 96,000 shares of common stock in the form of restricted stock units at $0.00 per share as equity compensation. The RSUs vest 33.33% on April 6, 2027, with the remaining 66.66% vesting in equal quarterly installments over the next two years, subject to continuous service. Following this award, he holds 96,000 shares directly.
Outset Medical, Inc. reported that its General Counsel, John L. Brottem, sold 2,842 shares of Common Stock at $3.35 per share in an open-market transaction. According to the footnote, this was a required “sell to cover” sale to satisfy tax withholding on 5,032 vesting RSU shares and was not a discretionary trade. Following the transaction, he directly owned 32,935 shares of Common Stock.
Outset Medical, Inc. Chair and CEO Leslie Trigg reported an open-market sale of 3,361 shares of Common Stock at $3.35 per share to cover tax withholding on vested RSUs. After this tax-related sell-to-cover transaction, Trigg directly holds 102,342 shares and indirectly holds 41,666 shares through the Trigg 2002 Rev Trust and 584 shares through the Trigg Family Trust.
Outset Medical, Inc. executive vice president Marc Nash reported an open-market sale of 1,817 shares of common stock at $3.35 per share. After this transaction, he holds 39,988 shares of Outset Medical common stock.
According to the disclosure, the shares were sold to cover tax withholding obligations arising from the vesting of 4,384 shares underlying restricted stock units granted on March 15, 2021, July 24, 2023, January 12, 2024 and June 10, 2025. The filing states this was a “sell to cover” transaction and not a discretionary trade by Nash.
Outset Medical, Inc. executive Marc Nash reported two sales of company common stock. On January 20, 2026, he sold 5,375 shares at $5.12 per share, followed by a sale of 980 shares at $4.98 per share on January 21, 2026, all held directly.
The footnote explains these 6,355 shares were sold to cover partial tax withholding obligations tied to the vesting of 14,839 RSU-based shares granted on June 10, 2025, and that the transactions did not represent discretionary trades by Nash. After these sales, he directly owned 41,805 shares of Outset Medical common stock.
Outset Medical, Inc.'s General Counsel, John L. Brottem, reported automatic sales of company common stock to cover tax withholding on recently vested equity awards. On January 20, 2026, he sold 9,314 shares of common stock at $5.12 per share, leaving him with 36,957 shares beneficially owned. On January 21, 2026, he sold an additional 1,180 shares at $5.01 per share, resulting in 35,777 shares beneficially owned afterward.
The filing explains that these 10,494 shares were the required number sold to partially cover tax withholding tied to the vesting of 17,997 shares of common stock underlying RSUs granted to him on June 10, 2025. The sales were executed as a “sell to cover” transaction for tax purposes and are described as not discretionary trades by the reporting person.
Outset Medical, Inc. insider filing shows tax-related share sales by Chair and CEO Leslie Trigg. On January 20, 2026, Trigg sold 11,794 shares of common stock at $5.12 per share, followed by a sale of 2,120 shares at $5.05 per share on January 21, 2026.
According to the footnote, these transactions were the required number of shares sold to cover partial tax withholding obligations tied to the vesting of 32,552 RSU-based shares granted on June 10, 2025, executed as a "sell to cover" and not as discretionary trades. After these sales, Trigg directly beneficially owned 105,703 shares of common stock and indirectly held additional shares through trusts.
Outset Medical, Inc. director Karen Prange reported an equity grant in the form of restricted stock units. On January 9, 2026, she was awarded 18,667 RSUs, each representing a contingent right to receive one share of Outset Medical common stock at a price of $0.00 per unit.
The RSUs vest quarterly over three years, conditioned on her continued service with the company through each applicable vesting date. Following this grant, she beneficially owns 18,667 shares of common stock directly.
Outset Medical executive Marc Nash reported a small, tax-related stock sale. On January 7, 2026, he sold 108 shares of Outset Medical common stock at $4.27 per share.
According to the footnote, the sale was required to cover tax withholding obligations tied to 289 shares underlying performance stock units that were earned based on performance criteria as of December 31, 2024 or January 6, 2025 and that vested and were released on January 6, 2025. The transaction was executed as a "sell to cover" and is described as not a discretionary trade by Nash.
After this sale, Nash directly beneficially owns 48,160 shares of Outset Medical common stock.
Outset Medical, Inc. reported that its General Counsel, John L. Brottem, sold 224 shares of common stock on 01/07/2026 at a price of $4.27 per share. After this transaction, he beneficially owned 46,271 shares directly.
The filing explains that the sale was a required "sell to cover" transaction to satisfy tax withholding obligations tied to 447 shares of common stock underlying performance stock units that had been earned and vested, and it did not represent a discretionary trade by Brottem.
Outset Medical, Inc. Chair and CEO Leslie Trigg reported a small sale of company stock that was made only to cover taxes. On January 7, 2026, she sold 1,795 shares of common stock at $4.27 per share in a transaction coded “S,” described as a “sell to cover” for tax withholding related to previously earned PSUs. According to the disclosure, this sale was required to satisfy tax obligations and “does not represent a discretionary trade.”
Following the sale, Trigg beneficially owned 119,617 shares of common stock directly, plus 41,666 shares held indirectly through the Trigg 2002 Rev Trust and 584 shares held indirectly through the Trigg Family Trust.
Outset Medical, Inc. (OM) reported an insider transaction by its Chair and CEO, Leslie Trigg. On 11/17/2025, Trigg sold 916 shares of common stock at $4.60 per share in a transaction coded “S.” The company notes this was a required sale to cover tax withholding tied to the vesting of 1,770 shares of common stock underlying restricted stock units granted on January 6, 2023 and January 12, 2024, and it did not represent a discretionary trade. After the transaction, Trigg beneficially owned 121,412 shares directly and additional shares indirectly through the Trigg 2002 Rev Trust and the Trigg Family Trust.
Outset Medical, Inc. (OM) reported an insider share sale by its EVP Operations R&D & Service, Marc Nash. On 11/17/2025, Nash sold 247 shares of common stock at $4.60 per share in a transaction coded "S," leaving him with 48,268 shares beneficially owned. The company explains that the shares were sold solely to cover tax withholding obligations tied to the vesting of 674 shares of common stock underlying RSUs granted on March 15, 2023, July 24, 2023, and January 12, 2024, and that the sale did not represent a discretionary trade by Nash.
Outset Medical, Inc. reported an insider transaction by its General Counsel, John L. Brottem. On 11/17/2025, he sold 388 shares of common stock at $4.6 per share. The sale was required to cover tax withholding obligations tied to the vesting of 748 shares of common stock underlying restricted stock units granted on January 6, 2023 and January 12, 2024, and is described as a non-discretionary "sell to cover" transaction. After this trade, he directly holds 46,495 shares of Outset Medical common stock.